NUWIQ®

Antihemophilic Factor (Recombinant)

SETH ROJHANI

PATIENT EDUCATOR • ATHLETE • ROLE MODEL

Receiving Personalized Prophylaxis with NUWIQ

Disclaimer: The views and opinions expressed in this testimonial are those of the patient and do not necessarily reflect the opinions or recommendations of Octapharma USA. Results vary from patient to patient and treatment should be discussed with your HCP.

“OBSTACLES ARE JUST SPEED BUMPS IN THE PATH OF LIFE.”

Seth believes that life presents all of us with challenges, but if we continue to work hard and think positively, good things will happen.

At age 28, Seth Rojhani is living proof that anything is possible. When he was just 6 months old, Seth was diagnosed with both severe Hemophilia A and cancer. A complication during tumor removal surgery caused T-2 level paraplegia, leaving Seth in a manual wheelchair ever since. “My situation was unique. Hemophilia was definitely a major issue, but there were other issues at the forefront for us as a family.”

As a Patient Educator for Octapharma, Seth shares the tools and resources that have allowed him to successfully maintain an active lifestyle while managing his bleeding disorder. “I love sports. Growing up, I was extremely active and I always wanted to do anything athletic. But from an early age, I was told ‘no’ because of the hemophilia. My mom and I had to really educate people on hemophilia and how it’s not something that will hinder you from doing a lot of things—as long as you treat your condition properly.”

Today, Seth lives in Denver, Colorado, plays for the Denver Rolling Nuggets as part of the National Wheelchair Basketball Association, and is a Paralympics bronze medalist with Team USA. He also coaches the Denver Jr Rollin’ Nuggets team.

Seth switched to NUWIQ 3.5 years ago. He was previously on a rFVIII, Xyntha® for 8 years, using a prophylactic regimen 3 times per week. “I was having some bleeds, and I wanted to reduce them. When NUWIQ came on the market, I hoped it would be a better choice for me—so I made the switch. The fact that it’s produced using human cells rather than hamster cells was also a factor.”

“For me, NUWIQ really helped put an end to the breakthrough bleeds that would sometimes limit me. Now, when I play basketball, I make sure to infuse before every game.”

Seth is on a personalized prophylaxis regimen. He describes the process of pharmacokinetic testing as relatively easy. “For me, it took just one day of testing. It’s been almost 4 years since starting on a personalized prophylaxis regimen, and it’s working for me very well. I have a good relationship with my physician and hemophilia treatment center. They know how active I am and understand the best way to treat me.”

“When talking to patients about NUWIQ, I ask first if their current treatment is working for them and are they happy with it? Are they happy with the results that they’re getting? From there, I go into my experience with NUWIQ and how it’s worked for me.”

Indications and Usage

NUWIQ® is a recombinant antihemophilic factor [blood coagulation factor VIII (Factor VIII)] indicated in adults and children with Hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and for routine prophylaxis to reduce the frequency of bleeding episodes. NUWIQ is not indicated for the treatment of von Willebrand Disease.

Please see enclosed full Prescribing Information.
Please see other side for Important Safety Information.

NUWIQ®
Antihemophilic Factor
(Recombinant)

What Matters Most When Choosing Your Hemophilia A Treatment?

NUWIQ Is the Only Recombinant FVIII Produced Using Human Cells

Without Chemical Modification or Protein Fusion

ZERO
Median ABR
Spontaneous Bleeds
in adults & children[1]

Median ABR for all bleeds was **0.9** in adults and **1.9** in children[1]

ZERO INHIBITORS
in prevoiusly treated patients who switched to NUWIQ (N=135)[1]



DOSING FLEXIBILITY
2.5 mL diluent volume
across ALL vials

Potential for
2X weekly infusions
with personalized prophylaxis[2]

Easy monitoring
by chromogenic or one-stage assay

Contraindications
NUWIQ® is contraindicated in patients who have manifested life-threatening hypersensitivity reactions, including anaphylaxis, to the product or its components.

Warnings and Precautions
Hypersensitivity reactions, including anaphylaxis, are possible with NUWIQ. Early signs of hypersensitivity reactions that can progress to anaphylaxis may include angioedema, chest tightness, dyspnea, wheezing, urticaria, or pruritus. Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur.

The formation of neutralizing antibodies (inhibitors) to Factor VIII can occur following the administration of NUWIQ. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests. If the plasma Factor VIII level fails to increase as expected, or if bleeding is not controlled after NUWIQ administration, suspect the presence of an inhibitor (neutralizing antibody).

Adverse Reactions
The most frequently occurring adverse reactions (>0.5%) in clinical trials were paresthesia, headache, injection site inflammation, injection site pain, non-neutralizing anti-Factor VIII antibody formation, back pain, vertigo, and dry mouth.

Please see enclosed full Prescribing Information.

References: 1. NUWIQ® full Prescribing Information. Hoboken, NJ: Octapharma USA Inc.; rev 2017.
2. Lissitchkov T, et al. Haemophilia. 2017;23:697-704.

Date of preparation: 10/2019. NUW-0220-COT

octapharma®
For the safe and optimal use of human proteins